A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma.

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA), but remains an intractable pharmacological target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here we demonstrate that expression o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Collisson, Eric A., Trejo, Christy, Silva, Jillian, Gu, Shenda, Korkola, James E., Heiser, Laura, Charles, Roch-Philippe, Rabinovich, Brian A., Hann, Byron, Dankort, David, Spellman, Paul T., Phillips, Wayne, Gray, Joe W., McMahon, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425446/
https://ncbi.nlm.nih.gov/pubmed/22628411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0347
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados